首页> 外文OA文献 >Fragment library screening identifies hits that bind to the non-catalytic surface of Pseudomonas aeruginosa DsbA1
【2h】

Fragment library screening identifies hits that bind to the non-catalytic surface of Pseudomonas aeruginosa DsbA1

机译:片段库筛选可识别与铜绿假单胞菌DsbA1非催化表面结合的命中

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

At a time when the antibiotic drug discovery pipeline has stalled, antibiotic resistance is accelerating with catastrophic implications for our ability to treat bacterial infections. Globally we face the prospect of a future when common infections can once again kill. Anti-virulence approaches that target the capacity of the bacterium to cause disease rather than the growth or survival of the bacterium itself offer a tantalizing prospect of novel antimicrobials. They may also reduce the propensity to induce resistance by removing the strong selection pressure imparted by bactericidal or bacteriostatic agents. In the human pathogen Pseudomonas aeruginosa, disulfide bond protein A (PaDsbA1) plays a central role in the oxidative folding of virulence factors and is therefore an attractive target for the development of new anti-virulence antimicrobials. Using a fragment-based approach we have identified small molecules that bind to PaDsbA1. The fragment hits show selective binding to PaDsbA1 over the DsbA protein from Escherichia coli, suggesting that developing species-specific narrow-spectrum inhibitors of DsbA enzymes may be feasible. Structures of a co-complex of PaDsbA1 with the highest affinity fragment identified in the screen reveal that the fragment binds on the non-catalytic surface of the protein at a domain interface. This biophysical and structural data represent a starting point in the development of higher affinity compounds, which will be assessed for their potential as selective PaDsbA1 inhibitors.
机译:在抗生素药物发现管道停滞的时候,抗生素的耐药性正在加速增长,这对我们治疗细菌感染的能力具有灾难性的影响。在全球范围内,我们将面对常见的感染会再次死亡的未来。以细菌引起疾病的能力而不是细菌本身的生长或存活为目标的抗毒力方法为新型抗菌剂提供了诱人的前景。它们还可以通过消除杀菌剂或抑菌剂施加的强大选择压力来降低诱导耐药性的倾向。在人类病原体铜绿假单胞菌中,二硫键蛋白A(PaDsbA1)在毒力因子的氧化折叠中起着核心作用,因此是开发新型抗毒力抗菌剂的有吸引力的目标。使用基于片段的方法,我们确定了与PaDsbA1结合的小分子。片段命中显示超过来自大肠杆菌的DsbA蛋白与PaDsbA1选择性结合,表明开发DsbA酶的物种特异性窄谱抑制剂可能是可行的。 PaDsbA1与屏幕上鉴定的最高亲和力片段共复合物的结构表明,该片段在域界面处结合在蛋白质的非催化表面上。此生物物理和结构数据代表了开发更高亲和力化合物的起点,将对其作为选择性PaDsbA1抑制剂的潜力进行评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号